Literature DB >> 11315344

Azathioprine therapy for patients with systemic lupus erythematosus.

M Abu-Shakra1, Y Shoenfeld.   

Abstract

Azathioprine is the only purine analog that is widely used for the management of systemic lupus erythematosus (SLE). For SLE patients without renal involvement, it is given to those patients who require a maintenance dose of 15 mg or higher of prednisone and for those who experience recurrent flares. Azathioprine in combination with steroids may be given to a large number of patients with lupus nephritis. It is also effective for patients with skin lesions, pneumonitis, thrombocytopenia or hemolytic anemia. Azathioprine may be used during pregnancy but not during lactation. It has not been shown to increase the risk for the development of malignancies among patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315344     DOI: 10.1191/096120301676669495

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

Review 1.  Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment.

Authors:  Deana Lazaro
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 2.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

3.  TPMT*26 (208F-->L), a novel mutation detected in a Chinese.

Authors:  Shirley Kow Yin Kham; Chin Kok Soh; Derrick Chen Wee Aw; Allen Eng Juh Yeoh
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

Review 4.  Clinical assessment and management of cytopenias in lupus patients.

Authors:  Alana B Levine; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

5.  Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.

Authors:  Sherry R Crowe; Joan T Merrill; Evan S Vista; Amy B Dedeke; David M Thompson; Scott Stewart; Joel M Guthridge; Timothy B Niewold; Beverly S Franek; Gillian M Air; Linda F Thompson; Judith A James
Journal:  Arthritis Rheum       Date:  2011-08

Review 6.  Treatment options for juvenile-onset systemic lupus erythematosus.

Authors:  Luis Carreño; Francisco Javier López-Longo; Carlos Manuel González; Indalecio Monteagudo
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

7.  Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.

Authors:  Mohamed A Kamal; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

8.  Azathioprine for ocular inflammatory diseases.

Authors:  Sirichai Pasadhika; John H Kempen; Craig W Newcomb; Teresa L Liesegang; Siddharth S Pujari; James T Rosenbaum; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; Eric B Suhler
Journal:  Am J Ophthalmol       Date:  2009-07-01       Impact factor: 5.258

9.  Quantitative in vitro and in vivo characterization of the human P32T mutant ITPase.

Authors:  Greg Herting; Katie Barber; Maria R Zappala; Richard P Cunningham; Nicholas E Burgis
Journal:  Biochim Biophys Acta       Date:  2009-11-13

Review 10.  Novel Approaches to Therapy for SLE.

Authors:  Gisele Zandman-Goddard; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.